No I think the actual worst case scenario is that he *appears* healthy to start the season, is pencilled into the lineup, and then gets knocked out for good midway through the season and we didn’t have the ability to sign a comparable quality player to replace him, because Klefbom came off of LTIR, thinking he could play again. So unless we retain Kulikov or a comparable player, our 2LD position may end up having the same problem as this season.
If Klefbom thinks he can play again, the only smart move is to pencil him in at 3LD. That way, if he overachieves, he can move up, but if he ends up back on the shelf injured, he’s not playing in the top 4, so we’ll have enough options to replace him internally (Russell/Lagesson etc). That would mean spending a bit more money than is ideal on D, but it might be worth it. If he comes back, he won’t have played in over a year anyway, so easing him back in on 3rd pairing is the smart move. And maybe in a 15min per game type of role he’ll stand a better chance of holding up for longer. I think he’d be agreeable to anything that allows him to keep playing, even if it means a significantly reduced role.